Investigating a new protein that regulates DNA damage and repair in triple negative breast cancer
CAPER, a New Regulator of DNA Damage and Repair in Triple Negative Breast Cancer
This study is looking at a protein called CAPER to see how it affects the way triple negative breast cancer cells handle DNA damage, with the hope of finding better treatments that can either kill these cancer cells or help them respond better to chemotherapy and radiation.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Saint Joseph's University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10359895 on NIH RePORTER |
What this research studies
This research focuses on triple negative breast cancer (TNBC), which is known for its poor clinical outcomes due to the absence of key hormone receptors. The study aims to explore the role of a protein called CAPER in DNA damage and repair mechanisms that are crucial for the survival of TNBC cells. By understanding how CAPER influences these processes, researchers hope to develop targeted treatments that can either kill TNBC cells or make them more responsive to existing therapies like chemotherapy and radiation. The approach involves knocking down CAPER expression in TNBC cells to observe the resulting effects on DNA damage and cell death.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who may benefit from novel treatment strategies.
Not a fit: Patients with other subtypes of breast cancer that express hormone receptors may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve survival rates for patients with triple negative breast cancer.
How similar studies have performed: While the specific role of CAPER in TNBC is largely unexplored, similar approaches targeting DNA repair mechanisms have shown promise in other cancer types.
Where this research is happening
Philadelphia, United States
- Saint Joseph's University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Mercier, Isabelle — Saint Joseph's University
- Study coordinator: Mercier, Isabelle
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.